Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers

• Published in: BMC neurology Vol. 24; no. 1; p. 116
• Main Authors: Lane, Roger M, Darreh-Shori, Taher, Junge, Candice, Li, Dan, Yang, Qingqing, Edwards, Amanda L, Graham, Danielle L, Moore, Katrina, Mummery, Catherine J
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09-04-2024; BioMed Central; BMC
• Subjects: Advertising executives; Age; Age factors in disease; Alzheimer Disease - cerebrospinal fluid; Alzheimer's disease; Amyloid; Amyloid beta-Peptides; Analysis; Analysis of covariance; Apolipoprotein E; Apolipoprotein E4; Apolipoprotein E4 - genetics; Apolipoproteins; Apolipoproteins E - genetics; Biomarkers; Butyrylcholinesterase; Butyrylcholinesterase - genetics; Care and treatment; Cerebrospinal fluid; Child; Cholinergic; Cognitive ability; Correlation analysis; Diagnosis; Equilibrium; Genetic aspects; Genotype & phenotype; Glial activation; Homozygotes; Humans; Hypotheses; Innate immune; Magnetic resonance imaging; Medicin och hälsovetenskap; Neurodegeneration; Neurodegenerative diseases; Pathology; Pathophysiology; Phenotype; Phenotypes; Polymorphism; Proteins; Tau protein; Variance analysis; Ventricle; Ventricles (cerebral); United Kingdom; Innate immune; Glial activation; Apolipoprotein E; Sex differences; Tau; Amyloid; Butyrylcholinesterase; Cholinergic
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/s12883-024-03611-5

The authors sought to examine the impact of the K-variant of butyrylcholinesterase (BCHE-K) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers.
Patients aged 50-74 years with cerebrospinal fluid (CSF) biomarker-confirmed AD, were recruited to clinical trial (NCT03186989 since June 14, 2017). Baseline demographics, disease characteristics, and biomarkers were evaluated in 45 patients according to BCHE-K and APOE4 allelic status in this post-hoc study.
In APOE4 carriers (N = 33), the mean age-at-diagnosis of AD in BCHE-K carriers (n = 11) was 6.4 years earlier than in BCHE-K noncarriers (n = 22, P < .001, ANOVA). In APOE4 noncarriers (N = 12) there was no observed influence of BCHE-K. APOE4 carriers with BCHE-K also exhibited slightly higher amyloid and tau accumulations compared to BCHE-K noncarriers. A predominantly amyloid, limited tau, and limbic-amnestic phenotype was exemplified by APOE4 homozygotes with BCHE-K. In the overall population, multiple regression analyses demonstrated an association of amyloid accumulation with APOE4 carrier status (P < .029), larger total brain ventricle volume (P < .021), less synaptic injury (Ng, P < .001), and less tau pathophysiology (p-tau
, P < .005). In contrast, tau pathophysiology was associated with more neuroaxonal damage (NfL, P = .002), more synaptic injury (Ng, P < .001), and higher levels of glial activation (YKL-40, P = .01).
These findings have implications for the genetic architecture of prognosis in early AD, not the genetics of susceptibility to AD. In patients with early AD aged less than 75 years, the mean age-at-diagnosis of AD in APOE4 carriers was reduced by over 6 years in BCHE-K carriers versus noncarriers. The functional status of glia may explain many of the effects of APOE4 and BCHE-K on the early AD phenotype.
NCT03186989 since June 14, 2017.